Impact of Antiplatelet and Anticoagulant Therapies on Platelet-related Prognostic Markers in Patients With Esophageal Cancer

Ishibashi, Yutaka; Tsujimoto, Hironori; Kasahara, Keita; Itazaki, Yujiro; Tsuchiya, Satoshi; Fujishima, Seiichiro; Yaguchi, Yoshihisa; Sugasawa, Hidekazu; Nomura, Shinsuke; Ito, Nobuyasu; Harada, Mine; Nagata, Hiromi; Shinto, Eiji; Kishi, Yoji; Ueno, Hideki

doi:10.21873/invivo.11991

Cited by 5 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(24), which are associated with survival in MDS. Third, large platelet cells might be associated with greater platelet-tumor complex formation; therefore, patients with a high P-LCR could gain more benefit from antiplatelet drugs than could patients with low P-LCR levels (25). Platelets play a critical role in the development and progression of different cancers by promoting cancer cell proliferation, survival, angiogenesis, and metastasis (26,27).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes

Chen

Zhang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundMyelodysplastic syndromes (MDSs) are a very heterogeneous group of myeloid disorders with high prevalence and risk of developing acute myeloid leukemia. The more accurate risk stratification can provide a better guidance of treatment. The platelet–large cell ratio (P-LCR) is a parameter reported in complete blood cell count tests, and was associated with many diseases, but its role in MDS is not clear.PurposeThis study aims to explore the impact of the P-LCR on the prognosis of patients with MDS, which is of great significance for clinical treatment.MethodsIn the retrospective study, 122 newly diagnosed MDS patients were enrolled. We used the bioinformatics tool X-tile to define a P-LCR threshold of 36.7% to predict prognosis. Patients were divided into P-LCRlow and P-LCRhigh groups, and their characteristics were compared between the two groups.ResultsResults show that the P-LCRlow was associated with worse overall survival (OS) than the P-LCRhigh patients (median OS, 18.53 months versus 25.77 months, p=0.0057), but there were no statistical differences in progression-free survival (PFS) between the two groups (p=0.2001). The results of univariate and multivariate Cox proportional hazard analyses adjusted for gender, bone marrow blast level, platelet count, and International Prognostic Scoring System scores showed that the P-LCR was useful in the evaluation of PFS [hazard ratio (HR) 0.212, 95%CI 0.064–0.702, p=0.011] and OS of MDS (HR 0.464, 95%CI 0.284–0.757, p=0.002).ConclusionThis study is the first report showing that the P-LCR would be a simple and immediately available biomarker for predicting the prognosis of MDS.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes

Chen

Zhang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In addition, the abnormal increase in D-dimer concent-ration can lead to blood stasis and provide a conducive environment for the hematogenous metastasis of tumor cells [ 18 ]. Consequently, a reciprocal cycle between tumor progression and the coagulation syst-em ensues, further emphasizing the potential significance of anticoagulant therapy in managing the ri-sk of metastasis and recurrence [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical value of measuring plasma D-dimer levels in patients with esophageal cancer

Chen,

Xu,

Zhang

et al. 2024

J Cardiothorac Surg

View full text Add to dashboard Cite

Background Esophageal cancer represents a significant public health concern; however, reliable diagnostic and prognostic markers have not been established. This study aimed to investigate the clinical value of plasma D-dimer levels in patients with esophageal cancer. Methods Overall, 120 patients with esophageal cancer who underwent radical surgical resection at our department between January 2019 and 2020 were included (esophageal cancer group). Plasma D-dimer levels were measured preoperatively and on postoperative days 1 and 14. Additionally, 60 healthy participants (control group) with measured plasma D-dimer levels were included. The preoperative D-dimer levels and positive D-dimer test rates were compared between the groups. The 3-year survival rate in patients with esophageal cancer was calculated using the Kaplan–Meier method. Results Preoperative D-dimer concentration in the esophageal cancer group was (0.65 ± 0.859 µg/mL) significantly higher than that in the control group (0.32 ± 0.369 µg/mL). The positivity rate in the esophageal cancer group (35.0%, 42/120) was significantly higher than that in the control group (15%, 9/60). D-dimer concentrations were significantly higher 1 day postoperatively than preoperatively. Conversely, D-dimer concentrations were significantly lower 14 days postoperatively than preoperatively. Patients in the esophageal cancer group with plasma D-dimer concentrations ≤ 0.5 µg/mL had significantly higher 3-year survival rates than those with higher concentrations. In the logistic multivariate analysis, tumor pathological stage and preoperative plasma D-dimer levels were independent prognostic factors of 3-year survival rates in patients with esophageal cancer. Conclusion Plasma D-dimer concentrations are clinically valuable in esophageal cancer diagnosis, postoperative recurrence monitoring, and prognosis prediction.

show abstract